阿托伐他汀对吸烟伴慢性肺源性心脏病患者临床疗效分析  

Therapeutic effectiveness of atorvastatin on chronic pulmonary heart disease in smokers

作　　者：朱颖[1] 张秀伟[1] 张郁青[1] 杨健[1] 

机构地区：[1]南京医科大学附属江宁医院,南京211100

出　　处：《军医进修学院学报》2010年第8期765-767,共3页Academic Journal of Pla Postgraduate Medical School

基　　金：江宁科技局基金资助(2007)

摘　　要：目的评价阿托伐他汀对吸烟伴慢性肺源性心脏病患者肺功能的影响。方法 55例吸烟伴COPD合并慢性肺心病、肺动脉高压患者随机分为阿托伐他汀组(AL组,27例)和常规治疗组(28例)。两组均接受常规治疗,阿托伐他汀组口服阿托伐他汀20mg/d,观察两组治疗前、治疗后6个月肺功能、超声心动图和6min步行距离的变化。结果阿托伐他汀组治疗6个月后肺动脉压较治疗前和常规治疗组治疗6个月时明显下降(P<0.05)、6min步行距离明显增加(P<0.05),FEV1、FEV1/FVC等肺功能指标比常规组治疗6个月后有明显改善(P<0.05);常规治疗组治疗前、治疗后6个月上述指标比较差异无统计学意义(P>0.05)。结论阿托伐他汀可以改善吸烟伴慢性肺源性心脏病患者生活质量及肺功能、降低肺动脉压。Objective To evaluate the effect of atorvastatin on pulmonary function in smokers with chronic pulmonary heart disease.Methods Fifty-five smokers with chronic obstructive pulmonary disease（COPD） complicated by chronic pulmonary heart disease were randomly divided into atorvastatin treatment group（n=27） and routine treatment group（n=28）.Patients in routine treatment were routinely treated and patients in atorvastatin treatment were treated with atorvastatin（20mg/d）.Changes in 6-minute walking test（6MWT）,pulmonary function and ultrasound cardiogram were observed before and after 6 months of treatment.Results The pulmonary arterial pressure was significantly lower,the 6MWT value was significantly higher,and the pulmonary function indexes including FEV1 and FEV1/FVC were much better in atorvastatin treatment group than in routine treatment group 6 months after treatment compared to 6 months before treatment（P0.05）.Conclusion Atorvastatin can effectively improve the life quality,pulmonary function and pulmonary arterial pressure of smokers with chronic pulmonary heart disease.

关 键 词：阿托伐他汀 肺疾病 慢性阻塞性 肺心病 肺动脉高压 

分 类 号：R563[医药卫生—呼吸系统]